Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 506 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizoaffective Disorder Clear all
Completed Not applicable Interventional Results available

Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

NCT01963676
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Auditory Hallucinations
Interventions
tDCS, Sham stimulation
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Lifestyle Modification for Weight Loss in Schizophrenia

NCT00990925
View directory record Official record
Conditions
Obesity, Schizophrenia, Schizoaffective Disorder
Interventions
Nutritional Lifestyle Modification Group, Usual Care
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

NCT01339858
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
Interventions
N-Acetyl Cysteine, sugar pill
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Building Employment Skills Through Therapy for Veterans

NCT01992913
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
integrated Cognitive Behavioral Therapy, Usual Care, Computerized cognitive remediation (CCR)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions
Eicosapentaenoic acid (omega-3 fatty acid), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01490086
View directory record Official record
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Interventions
RP5063, placebo, aripiprazole
Drug
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Theta Burst Stimulation for Schizophrenia

NCT03288779
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Theta Burst Stimulation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of Neural Stimulation in Individuals With Schizophrenia

NCT05746494
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
tDCS
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 4, 2026, 8:23 AM EDT
Withdrawn No phase listed Observational

Exercise Target Brain Oscillations in Psychosis

NCT05338424
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
Sprint Interval Training (SIT)
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Improving Care and Reducing Cost Study

NCT02364544
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychosis NOS
Interventions
Relapse Prevention Plan, Daily Support Website, Computer CBT for voices and paranoia, FOCUS, Prescriber Decision Assistant
Behavioral · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Lawrenceburg, Indiana • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Biomarkers in Schizophrenia

NCT00817336
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D Serine, Placebo
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

NCT00566735
View directory record Official record
Conditions
Major Depression, Bipolar Depression, Schizoaffective Disorder
Interventions
Razadyne, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant

NCT02415764
View directory record Official record
Conditions
Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions
Behavioral/Attitudinal OnTrack Role-Playing Game
Behavioral
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
18 Years to 30 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Needham, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 4, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional Results available

Sodium Nitroprusside in Early Course Schizophrenia

NCT04986072
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sodium Nitroprusside, 5% Dextrose solution
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 4, 2026, 8:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Targeting Individual Alpha Frequencies to Enhance Perceptual Timing

NCT04856657
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder
Interventions
Transcranial alternating current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness

NCT00500695
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivational Interviewing, Psychoeducation
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

NCT04779177
View directory record Official record
Conditions
Schizophrenia, Pediatric
Interventions
Lumateperone 42 mg, Lumateperone 28 mg
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia

NCT05643196
View directory record Official record
Conditions
Schizophrenia, Schizophrenia Schizoaffective
Interventions
PLIFUS, Sham PLIFUS, MRI
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 4 Interventional

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

NCT00391261
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions
Metformin
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Sep 4, 2026, 8:23 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Schizoaffective Disorder Using Mifepristone

NCT00725270
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
Interventions
Mifepristone, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT04512066
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo, Risperidone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 4, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 4, 2026, 8:23 AM EDT